Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy, radiotherapy and maintenance olaparib: An institutional case series and literature review.
Tsuchino Y, Chiyoda T, Jisaka M, Sakamaki T, Hirata M, Takahashi M, Yoshimura T, Sakai K, Wada M, Yamagami W. Tsuchino Y, et al. Among authors: yoshimura t. Gynecol Oncol Rep. 2024 Jun 24;54:101444. doi: 10.1016/j.gore.2024.101444. eCollection 2024 Aug. Gynecol Oncol Rep. 2024. PMID: 39035033 Free PMC article.
Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
Yoshihama T, Kuroda Y, Chiyoda T, Takahashi M, Yoshimura T, Saotome K, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Aoki D. Yoshihama T, et al. Among authors: yoshimura t. Int J Clin Oncol. 2022 Oct;27(10):1644-1650. doi: 10.1007/s10147-022-02212-x. Epub 2022 Jul 15. Int J Clin Oncol. 2022. PMID: 35835930
Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study.
Oishi M, Kasuga Y, Fukuma Y, Hamuro A, Tamai J, Tanaka Y, Hasegawa K, Yoshimura T, Ikenoue S, Ochiai D, Yamagami W, Tanaka M. Oishi M, et al. Among authors: yoshimura t. Int J Clin Oncol. 2023 Apr;28(4):587-591. doi: 10.1007/s10147-023-02297-y. Epub 2023 Jan 20. Int J Clin Oncol. 2023. PMID: 36662363
An exploratory cluster-randomized controlled trial on mindfulness yoga's effectiveness in school-refusing children: reductions in SCAS-C physical injury fears and pulse rate.
Kawazu S, Amitani M, Suzuki H, Amitani H, Monuki T, Wada M, Toyohira S, Hamada K, Yamamoto T, Yoshimura T, Mizuma K, Nishida Y, Watanabe H, Hirose M, Tagawa K, Ota K, Asakawa A, Owaki T. Kawazu S, et al. Among authors: yoshimura t. Front Hum Neurosci. 2024 Dec 11;18:1468729. doi: 10.3389/fnhum.2024.1468729. eCollection 2024. Front Hum Neurosci. 2024. PMID: 39736896 Free PMC article.
Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study.
Fukunaga K, Morishita A, Imachi H, Oura K, Sato S, Kobayashi T, Saheki T, Yoshimura T, Komori K, Nakahara M, Tadokoro T, Fujita K, Tani J, Kobara H, Murao K. Fukunaga K, et al. Among authors: yoshimura t. Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16157. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39726210
Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database.".
Noguchi Y, Suzuki K, Ino Y, Yoshimura T. Noguchi Y, et al. Among authors: yoshimura t. Clin Drug Investig. 2024 Dec 24. doi: 10.1007/s40261-024-01407-6. Online ahead of print. Clin Drug Investig. 2024. PMID: 39718695 No abstract available.
2,555 results